PURPOSE: To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvanttamoxifen or letrozolein the Breast International Group (BIG) 1-98 trial at 8.7 years of median follow-up. PATIENTS AND METHODS: This report analyzes 4,760 patients with breast cancer randomly assigned to 5 years ofmonotherapy with letrozole or tamoxifen in the BIG 1-98 trial with available information on BMI at randomization. Multivariable Cox modeling assessed the association of BMI with disease-free survival, overall survival (OS), breast cancer-free interval, and distant recurrence-free interval and tested for treatment-by-BMI interaction. Median follow-up was 8.7 years. RESULTS: Seventeen percent of patients have died. Obese patients (BMI ≥ 30 kg/m(2)) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m(2)), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m(2)) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively. CONCLUSION: There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI.
RCT Entities:
PURPOSE: To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8.7 years of median follow-up. PATIENTS AND METHODS: This report analyzes 4,760 patients with breast cancer randomly assigned to 5 years of monotherapy with letrozole or tamoxifen in the BIG 1-98 trial with available information on BMI at randomization. Multivariable Cox modeling assessed the association of BMI with disease-free survival, overall survival (OS), breast cancer-free interval, and distant recurrence-free interval and tested for treatment-by-BMI interaction. Median follow-up was 8.7 years. RESULTS: Seventeen percent of patients have died. Obesepatients (BMI ≥ 30 kg/m(2)) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m(2)), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m(2)) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively. CONCLUSION: There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI.
Authors: Georg Pfeiler; Robert Königsberg; Christian Fesl; Brigitte Mlineritsch; Herbert Stoeger; Christian F Singer; Sabine Pöstlberger; Guenther G Steger; Michael Seifert; Peter Dubsky; Susanne Taucher; Hellmut Samonigg; Vesna Bjelic-Radisic; Richard Greil; Christian Marth; Michael Gnant Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: Marco Colleoni; Anita Giobbie-Hurder; Meredith M Regan; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; István Láng; Ian Smith; Jacquie Chirgwin; Tadeusz Pienkowski; Andrew Wardley; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch Journal: J Clin Oncol Date: 2011-02-14 Impact factor: 44.544
Authors: Michael E Grossmann; Amitabha Ray; Katai J Nkhata; Dmitry A Malakhov; Olga P Rogozina; Soner Dogan; Margot P Cleary Journal: Cancer Metastasis Rev Date: 2010-12 Impact factor: 9.264
Authors: Henning Mouridsen; Anita Giobbie-Hurder; Aron Goldhirsch; Beat Thürlimann; Robert Paridaens; Ian Smith; Louis Mauriac; John F Forbes; Karen N Price; Meredith M Regan; Richard D Gelber; Alan S Coates Journal: N Engl J Med Date: 2009-08-20 Impact factor: 91.245
Authors: Evandro de Azambuja; Worta McCaskill-Stevens; Prudence Francis; Emmanuel Quinaux; John P A Crown; Malou Vicente; Rosa Giuliani; Bo Nordenskjöld; Jorge Gutiérez; Michael Andersson; Mireia Margeli Vila; Raimund Jakesz; Jan Demol; Joanna Dewar; Armando Santoro; Ana Lluch; Steven Olsen; Richard D Gelber; Angelo Di Leo; Martine Piccart-Gebhart Journal: Breast Cancer Res Treat Date: 2010-01 Impact factor: 4.872
Authors: Ying L Liu; Anurag Saraf; Benjamin Catanese; Shing M Lee; Yuan Zhang; Eileen P Connolly; Kevin Kalinsky Journal: Breast Cancer Res Treat Date: 2017-09-25 Impact factor: 4.872
Authors: Meritxell Bellet; Kathryn P Gray; Prudence A Francis; István Láng; Eva Ciruelos; Ana Lluch; Miguel Angel Climent; Gustavo Catalán; Antoni Avella; Uriel Bohn; Antonio González-Martin; Roser Ferrer; Roberto Catalán; Analía Azaro; Agnita Rajasekaran; Josefa Morales; Josep Vázquez; Gini F Fleming; Karen N Price; Meredith M Regan Journal: J Clin Oncol Date: 2016-01-04 Impact factor: 44.544
Authors: Jennifer A Crozier; Alvaro Moreno-Aspitia; Karla V Ballman; Amylou C Dueck; Barbara A Pockaj; Edith A Perez Journal: Cancer Date: 2013-04-12 Impact factor: 6.860
Authors: James N Ingle; Junmei Cairns; Vera J Suman; Lois E Shepherd; Peter A Fasching; Tanya L Hoskin; Ravinder J Singh; Zeruesenay Desta; Krishna R Kalari; Matthew J Ellis; Paul E Goss; Bingshu E Chen; Bernhard Volz; Poulami Barman; Erin E Carlson; Tufia Haddad; Matthew P Goetz; Barbara Goodnature; Matthew E Cuellar; Michael A Walters; Cristina Correia; Scott H Kaufmann; Richard M Weinshilboum; Liewei Wang Journal: Clin Cancer Res Date: 2020-02-25 Impact factor: 12.531
Authors: Otto Metzger Filho; Anita Giobbie-Hurder; Elizabeth Mallon; Barry Gusterson; Giuseppe Viale; Eric P Winer; Beat Thürlimann; Richard D Gelber; Marco Colleoni; Bent Ejlertsen; Marc Debled; Karen N Price; Meredith M Regan; Alan S Coates; Aron Goldhirsch Journal: J Clin Oncol Date: 2015-07-27 Impact factor: 44.544